Pfizer will list its COVID-19 treatment Paxlovid at a price of $1,390 per five-day course when it soon hits the commercial market, the drugmaker confirmed to Axios.

Why it matters: Paxlovid’s new listed price, first reported by the Wall Street Journal, will be more than twice the $529 paid by the federal government, which until now has maintained the entire U.S. supply of the key antiviral medication.

  • WhatAmLemmy@lemmy.world
    link
    fedilink
    arrow-up
    155
    arrow-down
    4
    ·
    1 year ago

    Magnificent! You’ve successfully constructed and attacked a straw-man by conflating economics with medical science, and displayed your total ignorance of … everything … in the process…